Podcasts about clinical affairs

Real-World Evidence (RWE) is transforming how regulators evaluate medical devices — but many manufacturers still struggle to use it correctly. In this episode, we break down what RWE really means, how it differs between the FDA and the EU MDR, and how you can design a compliant, global strategy that turns data into regulatory strength. You'll learn: What qualifies as Real-World Data (RWD) and Real-World Evidence (RWE) How the FDA integrates RWE into premarket submissions (510(k), De Novo, PMA) How EU MDR uses RWE through PMCF and PMS The key differences in approach between the two regions A practical 5-step roadmap to build a compliant RWE strategy Common pitfalls (bias, poor traceability, privacy issues) — and how to avoid them

Dr. Dipen J. Parekh is a globally renowned urologic oncologist, healthcare innovator, and leader in academic medicine. He was appointed Executive Vice President for Health Affairs at the University of Miami and Chief Executive Officer of its health system (UHealth) on June 1, 2025. He remains Founding Director of the Desai Sethi Urology Institute and is an accomplished researcher and professor at the University of Miami Miller School of Medicine who holds the Victor A. Politano Endowed Chair in Urology and is widely celebrated for his groundbreaking contributions to the field of robotic-assisted urologic oncology. Having served as Chief Operating Officer of UHealth from 2020-2025, Chief Clinical Officer from 2017-2020, Chairman of the Department of Urology since 2012, Executive Dean of Clinical Affairs at the University of Miami Miller School of Medicine, and Director of Robotic Surgery for UHealth, Dr. Parekh brings a wealth of academic, clinical, administrative, and institutional experience to the role.Over the course of his career, Dr. Parekh has performed more than 6,000 robotic urologic cancer surgeries, making him one of the most experienced practitioners worldwide. He led the groundbreaking RAZOR trial, published in The Lancet in 2018, which established the efficacy of robotic-assisted radical cystectomy as comparable to open surgery for bladder cancer. He is an NCI funded surgeon scientist with over 200 peer reviewed publications in urologic oncology. His dedication to innovation has also included establishing advanced robotic surgery programs in academic centers across the globe.

Tyler O'Malley is the Vice President of Clinical Affairs, Bioinformatics, and Market Access at Exagen, Inc. Tyler shares his journey in the MedTech industry and discusses Exagen's innovative approaches to autoimmune testing solutions, including cutting-edge diagnostics for lupus and other diseases. With over a decade of experience, Tyler provides insights into the challenges and breakthroughs in the field, highlighting the significance of early diagnosis and personalized treatment, while also discussing the challenges and opportunities in effective leadership during different stages of company growth.   Guest links: https://exagen.com/ Charity supported: Save the Children Interested in being a guest on the show or have feedback to share? Email us at theleadingdifference@velentium.com.  PRODUCTION CREDITS Host & Editor: Lindsey Dinneen Producer: Velentium Medical   EPISODE TRANSCRIPT Episode 066 - Tyler O'Malley [00:00:00] Lindsey Dinneen: Hi, I'm Lindsey and I'm talking with MedTech industry leaders on how they change lives for a better world. [00:00:09] Diane Bouis: The inventions and technologies are fascinating and so are the people who work with them. [00:00:15] Frank Jaskulke: There was a period of time where I realized, fundamentally, my job was to go hang out with really smart people that are saving lives and then do work that would help them save more lives. [00:00:28] Diane Bouis: I got into the business to save lives and it is incredibly motivating to work with people who are in that same business, saving or improving lives. [00:00:38] Duane Mancini: What better industry than where I get to wake up every day and just save people's lives. [00:00:42] Lindsey Dinneen: These are extraordinary people doing extraordinary work, and this is The Leading Difference. Hello, and welcome back to another episode of The Leading Difference podcast. I'm your host, Lindsey, and I am so excited to introduce you to my guest today, Tyler O'Malley. Tyler serves as Associate VP of Clinical Affairs and Market Access at Exagen, Inc., a leader in autoimmune testing solutions. In his role, he oversees clinical trials, bioinformatics, and medical policy development for Exagen's current diagnostic portfolio and pipeline of proprietary solutions. With more than a decade of experience, O'Malley has contributed to more than a dozen clinical trials focusing on clinical validity and utility evidence for autoimmune diagnostics. His expertise is widely recognized with numerous publications in esteemed peer reviewed journals, and notably, he's the first author of one of the largest clinical utility studies in lupus diagnostics. O'Malley graduated from Georgia Gwinnett College with a Bachelor of Science in biology, concentrating in biochemistry. His 11 year career in research and development and medical affairs encompass medical science, education, assay development, and clinical research coordination. Well, welcome to the show, Tyler. I'm so excited to have you here today. [00:02:01] Tyler O'Malley: Thanks, glad to be here. [00:02:02] Lindsey Dinneen: Yeah, absolutely. Well, I would love just starting off by telling us a little bit about yourself, your background, and what led you to MedTech. [00:02:11] Tyler O'Malley: Sure. So, I'm the Vice President of Clinical Affairs, Bioinformatics, and Market Access at Exagen. We're a specialty diagnostics company focused on autoimmune rheumatic diseases. So we develop proprietary testing technology for conditions like lupus, rheumatoid arthritis, Sjogren's disease, as well as many others. And yeah, our focus is trying to find solutions for patients who are dealing with what are many times challenging chronic diseases that can present themselves in very mysterious ways oftentimes. And so, these are challenges that patients have that have, for the most part, gone unsolved for many decades, and so there's a lot of opportunity out there. In terms of, myself, my background, I've been with Exagen for the past 11 and a half years. So I've been doing this for a while now, and I've worked in a couple of different areas within the organization, doing work within the lab assay development, as well as outside the lab doing clinical research, statistical analysis, which led to the bioinformatics role. And then as well as doing some work trying to align our clinical evidence with medical policy for our tests which is the market access role. So, a little bit of everything, but there are some through lines that I assure you do make some sense if you really think about it. [00:03:33] Lindsey Dinneen: Excellent. Excellent. Well, thank you for sharing a little bit about that. There's so much to dive into, but going back a little bit in your story, when you were thinking about careers-- you're a eager high school student ready to embrace college, and you're ready for the next step --is this something that you could have imagined yourself doing or has this always been a passion of yours? Or is this something you kind of found yourself in? [00:03:57] Tyler O'Malley: Not at all. So, no I, so I will say I've always been interested in autoimmunity. So that's always been something that has always piqued my interest, whether I was in high school or college. And so I guess in that sense, it's not a surprise. But the laboratory diagnostics component of it was not something that was on my radar when I was in high school or college. And I guess the journey to Exagen was, after graduating from high school, went and got a bachelor's degree in biology with a biochemistry focus. So, that's sort of my background there. And while I was getting the degree and focusing on biochemistry, I had the opportunity through a resource scholarship at Georgia Tech to work in a graduate lab, which was a really interesting experience where, you know, for a little over a year I had the opportunity to work alongside PhD candidates, postdocs, on a research project that was partially funded and get the experience and understand what it's like to work towards a PhD and what it would look like to kind of go down that path of graduate level research. And I think it had the opposite effect that it was intended to have in that it kind of showed me I didn't want to do that. So, I think in a lot of ways I was happy I had that experience 'cause it showed me before I went down that path that it was something I didn't wanna do. Nothing against it, I guess I wanted to do something that maybe had more of a translational impact, a little bit closer to the patient. And so, finished my degree, and at the time I was living in Georgia, so I finished my degree in Georgia, left and moved out to California, and ended up at Exagen by pure chance through a recruiter. And that was back in 2014, and basically just joined Exagen at the time when it was a smaller company, and grew with the company, and was fortunate enough to have the ability to learn a lot of different functions within the company as it grew, and there were a lot of different things that needed to be done a as the company was growing. And so it, it's been kind of a, an interesting ride since then. [00:06:08] Lindsey Dinneen: Yeah, absolutely. And of course all of those different experiences, I'm sure, have woven their way in, like you said. Sometimes you have to kind of look for that line, but there is one that's, apparent when you look back. So, can you talk a little bit more about the company, what it does, especially in regards to its testing technology, and I'd love to hear about some of the innovation that's just coming out of this incredible organization you're a part of. [00:06:35] Tyler O'Malley: Sure. So our our testing, again, primarily focuses on addressing unmet needs in patients who have autoimmune connective tissue diseases. And specifically we have some proprietary technology around biomarkers that help diagnose systemic lupus. And lupus is kind of the prototypical autoimmune disease in that it can manifest in just about any different way. It can show up in your skin, your heart, your lungs, your kidneys, just about any way you can imagine, and sometimes in multiple different ways. And so in that way, it can be challenging to diagnose 'cause it can look like so many different things. And much of the testing that is used for lupus or has been used traditionally is very antiquated. Antibody tests that were developed many decades ago that have been refined to some extent over the years, but for the most part are not overly sophisticated. So, what Exagen has done over the past 15 or so years is brought forward some technology, that was originally licensed from University of Pittsburgh, looking at measuring a form of the complement system, which is a part of our immune system. It's a very ancient form of our immune system. It's a collection of proteins that come together to help fight off pathogens and help clear debris to keep our our immune system healthy. And what we're able to do is measure essentially the buildup of a complement fragment that builds up on your red blood cells and on your B lymphocytes. And what this does is it gives us a unique ability to detect lupus that's much more sensitive than the conventional means. And what that means, when I say sensitivity, is that it's able to pick up more lupus patients than the conventional testing. So, one way of thinking about this is like, if you have a hundred patients in a room that all have lupus, right? Because they've been assessed by a doctor, they've been clinically diagnosed, and you were to test them, and say your conventional test is 50% sensitive, meaning half of the room would test positive on this test and the other half would test negative. This test that we're talking about here, it would pick up two thirds of the room, right, as opposed to conventional testing, which would pick up fewer patients. So, that's the kind of technology that we're trying to develop here, which is trying to be more inclusive, pick up more patients sooner, give better insights to physicians to combine with their clinical assessments such that patients can get earlier treatments and hopefully stave off some of the more kind of disastrous outcomes of the disease that come with not getting treated soon enough and not getting treated appropriately for their symptoms. [00:09:31] Lindsey Dinneen: Yeah, of course. That's incredibly important and I'm so glad that the company is working to create those solutions, like you said, because previous methods while maybe somewhat useful, are more antiquated at this point. And so it's really important to have these new strides in innovation. So as you're dealing with all of this, I'm sure that there are stories that have come up about real people having impacted lives because of the technology that your company is bringing. Do you have any examples that you could share with us about that? [00:10:05] Tyler O'Malley: Sure. Yeah, there's been a number of individuals that we've had the fortune of meeting over the years. And they come and share the story with our team. We like to bring folks in with, for example, when we bring on new sales team members, we try to bring on a patient just to be able to share their story. So, recently we had an individual, who is connected to someone who works in our organization-- again, just pure chance-- who happened to have a very unique story. So first of all, lupus, for those who don't know, is a condition that primarily affects women. Lupus is a disease that affects women at a ratio of nine to one, nine to one female to male or so, in other words, around 90% of lupus patients are women. But that's not to say that it isn't an issue for that subset of of men that do develop lupus. And in fact, the disease tends to be more severe in that 10% of lupus patients that are men. So this individual who we've had the chance to meet and hear his story, really interesting because he's-- you would never know if you met this guy-- because he's a CrossFit guy. He is probably the healthiest guy you can imagine looking at him. But he went a harrowing journey to get to his diagnosis. And it all started with, relatively -- well, I don't wanna downplay it-- but let's call it "less severe symptoms" like alopecia and rashes, things like this that sort of make you think, "Well, gee, that's strange," or "I wonder what that is all about." And then leading up to much, much more severe symptoms like severe edema and pericarditis that was ultimately life threatening. And ultimately, he was able to get the right testing and get to the right doctors, but it was not a short journey from the time that these symptoms initially presented themselves to the time where he was able to get to the test and to get to the right diagnosis and onto the right treatment. The good news is, he's in a much better place now after finding out what's causing his symptoms and getting to a treatment management plan that works for him and he's even back to getting to an exercise routine that works for him. It's maybe not exactly the same as what it was before, but I mean, that's the thing. Now, you can lead a relatively normal life with lupus. It wasn't that long ago, call it several decades ago, where the mortality rate for lupus was as high as 50% in the first year after diagnosis. Treatment advances have greatly improved that and have changed the lives of people who live with Lupus now, but it used to be a very severe diagnosis. It still is, but it's very manageable now. [00:12:54] Lindsey Dinneen: Wow. Yeah. And so catching it and having that answer to, like you said, really difficult health journey where you're just not sure what's going on. And I really appreciate you talking a little bit about how Lupus looks different and manifests itself differently in different circumstances so it can be difficult to initially diagnose. So I love the fact that the company is focusing on things like that, when caught early can maybe make a huge difference in somebody's life like the gentleman you mentioned. Thank you for sharing about that. So now your own career has been really interesting in that you have gotten to do a lot of different things within the company and learn so much. Now as you've continued to grow with the company, you've, I'm sure, developed a lot of different leadership skills along the way, and I'm curious what it's been like in that sense of your journey to embrace leadership and how do you go about it? What have you found works really well, and maybe what advice would you have for somebody who's a little bit earlier in their career? [00:13:58] Tyler O'Malley: Yeah. Really interesting question. And I, I guess, my experience was, I came into an organization that was, I think at the time, maybe in the entire company was maybe 60, 70 people. So, as you can imagine, it was a very flat organization. I reported directly to the Chief Scientific Officer when I first joined the organization as a relatively low level R&D employee. So that afforded me, I think, a unique opportunity because I was often involved with project planning and discussions that I don't know that you get that opportunity in different types of corporate settings. And I think what has proven very useful in terms of my development, and as I look back and reflect on kind of what's led me here is, I can just recall, so, so many times, especially early on in, in a startup-- which can sometimes be chaotic and there's a lot of moving parts and things are moving fast-- there would be times where I would be in meetings where I wasn't necessarily expected to do very much, I think, or contribute much. And I would just sort of observe, right? And I think there's so much you can learn through not just listening to the conversation, but the body language of the people around the table. The way that people present, the way that people take criticism, the way that they respond. It was almost like a, it was a lesson every day just watching that. And I think where I thrived and maybe added value at times was realizing when people were talking past one another and just, at times, trying to find a way to come into that and say, "Well, right, but did you consider maybe what this person was trying to communicate here?" And, you can't always resolve those sorts of situations, but sometimes you can. And that's really valuable when you can help two individuals get past an impasse like that. So, and I think it helps you build credibility doing that too, being a bridge builder in that sense. And, and I think, that was something I don't know-- whether intuitively or purely by accident, I don't know-- I figured out over time was that, maybe as a young person in your career, sometimes it can be easy to get caught up on sort of the X's and O's of your job, whatever it is that you're doing-- if you're a computer programmer, you're doing bioinformatics or whatever the case may be-- you can get really caught up in the technical skills that you're trying to hone and develop. But there's so many soft skills that you have to build as well at the same time. And there's the relationships that you build, as well, that you don't know when you're gonna need them or when they'll pay off. But things change at organizations and you're glad when you have those relationships when it comes time to need them. [00:16:51] Lindsey Dinneen: Yeah. Absolutely. Yeah. I love your discussion on the idea of being a bridge builder, because I've been thinking a lot about that recently where there's so much unintentional missed communication, just literally just passing by where, one person is saying something, the other person's saying something, and as an outsider, you're able to have a little bit of a distance to go, "Oh, you're kind of saying the same thing, but I'm not sure that you guys realize that, and here's how." Yeah, that translating is a really important skillset and a fun one when you can nail it down. So as you look towards the future of your own career and the company's trajectory, what are some things that you're looking forward to? [00:17:35] Tyler O'Malley: Well, we obviously have a number of exciting pipeline initiatives that bring a lot of energy to me as I think about what we're trying to do going forward. I'm excited about where the company is headed in terms of its trajectory. I've described my time at the company as, even though I've been at the same company for 11 and a half years or so, I really feel like I've worked for three different companies in that time, in that, there was a period of time that was a startup up until the point the company went public. And then there was this time from when the company was public, where we raised a lot of money, there were a lot of expectations and didn't exactly kind of work out exactly as we had hoped. And then there was a leadership change. And now we're sort of in this third phase now where the arrow's pointing up and we have realigned our strategy here and we found a way to be sustainable and to be able to continue to build on something where hopefully we can continue to find interesting technology that's out there. We have an ongoing partnership with, as an example, Johns Hopkins University to try to develop a test to help address lupus nephritis. So this is a particular form of organ manifestation of lupus. It's one of the more common manifestations of lupus, and one of the more devastating forms of lupus, in that almost 50% of lupus patients will have kidney involvement at some point in their disease. And as much as 10 to 20% of patients who do have lupus nephritis will go on to unfortunately develop end stage kidney disease and require dialysis or kidney transplant. So it's obviously life altering and can be, very impactful to individuals. So, to be able to work on something like that and be able to potentially alter the trajectory of someone's life in that way is pretty cool to think about. And, not everyone gets to do that. I mean, it's not that other jobs aren't meaningful, it's just not everyone gets the opportunity to do that kind of thing. And if you can also find joy in what you're doing in your job. I think that's also great too. I mean, it's really cliche, the things people say, and so I won't do it. The whole, like, " If you like what you do, you never work." Believe me, it's work. I do feel like I'm working sometimes, for sure, but I can't complain. I do, for the most part, have fun with what I'm doing. I'm fortunate enough, I have a great team of people, well-- three teams of people-- that I really enjoy working with, and being able to work with people and see them grow and develop and be a part of that is also super rewarding as well too. So, yeah, I'm just, I'm having a lot of fun. [00:20:26] Lindsey Dinneen: Yeah. Excellent. Wonderful. Well, gosh, I'm gonna pivot the conversation just for fun a little bit. Imagine that you were to be offered a million dollars to teach a masterclass on anything you want. Now, this could be within your industry, but it doesn't have to be. What would you choose to teach? [00:20:45] Tyler O'Malley: I think that-- maybe this is kind of fun, probably not-- but I think that ,I don't know why, and it's funny because it's-- I don't even know if this qualifies because I don't even know how I would teach it-- but I think I'm fairly good at guesstimating numbers and it's really useful in that it helps in a lot of different situations to be able to shortcut math. And to be clear, it's not that I'm doing long division in my head or anything like that, but it's, if you can kind of shortcut and get the approximate number, it can be really useful. And it's a nice kind of party trick too kind of thing. Again, I don't know how I would teach it 'cause it's sort of like it's up here, and I don't know how I would externalize that, but yeah, that's something I feel like would be kind of cool to figure out how I could teach that. [00:21:35] Lindsey Dinneen: Absolutely. Yeah. It's a superpower. So it would be very cool to try to then-- you've got this innate ability-- so then to try to break it down into how does somebody else develop the skill sets that you just sort of possess, and go from there. That would be really entertaining. I love it. Great answer. Okay. And then the next question is, how do you wish to be remembered after you leave this world? [00:21:59] Tyler O'Malley: Yeah. Well, that's a deep question. I think that the most meaningful impact that you can have is the impression you leave on the people that you interacted with, right? And I think, for me, I would just hope that the people that I've had the chance to spend time with-- obviously family, friends, people I worked with, people who worked on my teams-- I would just hope that as they would reflect on the time that we had together, that it would be a memory that was time well spent and that hopefully there are some good shared experiences that we had and that hopefully I left something that was meaningful. But as it relates to the work that we're doing, I hope that the impact that we're having-- some of it has a longer reach than even what we can see today, 'cause I think, truly being selfless is trying to build things that you'll never realize the benefit of: planting trees that you'll never sit under yourself. It's for someone else down the line in the future. [00:23:14] Lindsey Dinneen: Yeah. Yeah. I love thinking about it in those terms too: being willing to do your bits of good and let them go out into the world and not necessarily know the ripple effects and still use that as a worthwhile use of your time. I love that. And then final question, what is one thing that makes you smile every time you see or think about it? [00:23:39] Tyler O'Malley: Yeah, I think the easy answer is probably my kids. So I have two kids, and that's kind of the reprieve from the work life and kind of focusing on all this important stuff that we're trying to do here at work, but being able to kind of break away from that and focus on building them up and watching them grow and develop and become their own person is really cool. It's obviously a unique experience and it's a nice thing to be able to think about when you need something to kind of bring you back up. [00:24:12] Lindsey Dinneen: Yeah, absolutely. Just a different way of looking at the world from such a fun perspective. I love that. [00:24:19] Tyler O'Malley: Yeah. [00:24:20] Lindsey Dinneen: Yeah. Well, Tyler, this has been such a great conversation. I so appreciate your time today telling us a little bit about your story, the company, and all the incredible work that you guys are doing to change lives for a better world. And we are so honored to be making a donation on your behalf as a thank you for your time today to Save the Children, which works to end the cycle of poverty by ensuring communities have the resources to provide children with a healthy, educational, and safe environment. So thank you so much for choosing that charity to support, and thank you so much for being here and thank you for doing what you do. [00:24:59] Tyler O'Malley: Thank you. It's it's been a pleasure. [00:25:01] Lindsey Dinneen: Excellent, and thank you also to our listeners for tuning in, and if you're feeling as inspired as I am, I'd love it if you'd share this episode with a colleague or two and we'll catch you next time. [00:25:14] Dan Purvis:  The Leading Difference is brought to you by Velentium Medical. Velentium Medical is a full service CDMO, serving medtech clients worldwide to securely design, manufacture, and test class two and class three medical devices. Velentium Medical's four units include research and development-- pairing electronic and mechanical design, embedded firmware, mobile app development, and cloud systems with the human factor studies and systems engineering necessary to streamline medical device regulatory approval; contract manufacturing-- building medical products at the prototype, clinical, and commercial levels in the US, as well as in low cost regions in 1345 certified and FDA registered Class VII clean rooms; cybersecurity-- generating the 12 cybersecurity design artifacts required for FDA submission; and automated test systems, assuring that every device produced is exactly the same as the device that was approved. Visit VelentiumMedical.com to explore how we can work together to change lives for a better world. 

Guest: Eric Ruderman, MD Combined dermatology–rheumatology clinics are transforming psoriatic disease care by streamlining communication, reducing patient burden, and enabling more targeted, effective treatments. To learn more about how these clinks work and why they matter for patients with psoriatic disease, tune in to hear from Dr. Eric Ruderman, Professor of Medicine and the Associate Chief of Clinical Affairs for the Division of Rheumatology at Northwestern University Feinberg School of Medicine.

Cancer, Character, and Calling: The Oncologist's Journey, hosted by Girindra Raval, MD, is a podcast highlighting how top oncologists have navigated the field over the course of their careers, the passion that drove them to enter the oncology space, and the ongoing work that will continue to transform cancer care. Each episode, Raval will sit down with a top oncologist to dive into their background, highlight their career achievements, discuss key issues still being addressed in their field, and explore their interests outside of the clinic and lab. In this episode, Raval welcomed Anand Jillella, MD, who is the J. Harold Harrison, MD Distinguished University Chair in Medicine, a professor of medicine & pediatrics, and chief of the Division of Hematology/Oncology at Augusta University Medical College of Georgia. He is also associte director of Clinical Affairs and director of the Georgia Cancer Center Clinic, Ambulatory Services, and Network and Outreach. Their conversation focused on discussed Jillella's career journey, starting from his oncology internship in 1989 to establishing a bone marrow transplant program. Jillella noted the initial successes of the program that led to its exponential growth over the years. He also emphasized the importance of community outreach and collaboration with referring practices, explaining the early work that he and colleagues did to maintain working relationships with other practices and get the program on the map. Furthermore, Jillella highlighted the historical development of the treatment algorithm for patients with acute promyelocytic leukemia, emphasizing that proper physician training and research significantly reduced mortality rates in this disease over the years. Raval and Jillella concluded by addressed the evolving landscape of oncology, the growing effects of AI tools on medical practice patterns, and the need for academic institutions to stay on the cutting edge of new treatments and technologies to advance the field and ultimately improve patient care.

This October, the Irish Cancer Society is calling for people to host a Big Pink Breakfast and help fund their vital cancer supports and services, like night nurses, counselling and life-changing breast cancer research. To hear more about the services the Irish Cancer Society provides, and how you can host a Big Pink Breakfast, we heard from Patrice Morrisey, a mother of three who was diagnosed with breast cancer in May 2023, and Amy Nolan, Director of Clinical Affairs at the Irish Cancer Society.For more information www.cancer.ie/pink.

This October, the Irish Cancer Society is calling for people to host a Big Pink Breakfast and help fund their vital cancer supports and services, like night nurses, counselling and life-changing breast cancer research. To hear more about the services the Irish Cancer Society provides, and how you can host a Big Pink Breakfast, we heard from Patrice Morrisey, a mother of three who was diagnosed with breast cancer in May 2023, and Amy Nolan, Director of Clinical Affairs at the Irish Cancer Society.For more information www.cancer.ie/pink.

In this important episode of Transmission Interrupted, host Jill Morgan is joined by a distinguished panel of experts to provide a comprehensive update on respiratory illness trends for the 2025 season. Dr. Ryan Maves (infectious diseases and critical care medicine, Wake Forest University), Dr. Kari Simonson (pediatric infectious diseases, University of Nebraska Medical Center), and Dr. John Horton (clinical affairs, gynecology and obstetrics, Emory University) share the latest data and evidence-based recommendations for healthcare providers and the public.The discussion covers the full spectrum of respiratory viruses currently impacting our communities, including influenza, RSV, COVID-19, and pertussis. The panel addresses the unique risks facing infants, children, pregnant individuals, older adults, and those with underlying health conditions. Listeners will gain valuable insight into current vaccine guidance, the role of updated testing strategies, and protective measures that go beyond vaccination—such as proper mask use, respiratory and hand hygiene, and the importance of source control and eye protection.This episode offers practical guidance for both healthcare workers and the public as we enter another busy respiratory virus season. Drawing on real-world experience and the latest research, our guests emphasize steps we can all take to reduce transmission, protect vulnerable populations, and maintain safety in both clinical and home settings.GuestsJohn Patrick Horton, MD, MBAVice Chair of Clinical Affairs for Gynecology and Obstetrics Emory UniversityDr. John Horton is the Vice Chair of Clinical Affairs for Emory University's Department of Gynecology and Obstetrics. He also serves as Emory Healthcare's Division Director for General Gynecology and Obstetrics, and Interim Operations Director for the Gynecologic Specialties Division. Additionally, Dr. Horton is the Director of the Obstetric Rapid Response Team at Emory Healthcare and is Associate Professor at the Emory University School of Medicine Department of Gynecology and Obstetrics. Ryan Maves, MD, FCCM, FCCP, FIDSAProfessor in Infectious Disease and Critical Care MedicineOffice of Global HealthWake Forest UniversityDr. Ryan Maves is a Professor of Medicine at the Wake Forest University School of Medicine in Winston-Salem, North Carolina, where he serves as medical director of transplant infectious diseases and as a faculty intensivist at North Carolina Baptist Hospital. A graduate of the University of Washington School of Medicine, he entered active duty in the U.S. Navy in 1999. He completed his residency in internal medicine and fellowships infectious diseases and critical care medicine at Naval Medical Center San Diego. During his military service, he served as the flight surgeon for Carrier Air Wing SEVENTEEN embarked onboard the USS George Washington (CVN-73), at the Naval Medical Research Unit No. 6 in Lima, Peru, conducting preclinical and clinical studies in antimicrobial drug resistance and vaccine development, as director of medical services at the NATO Role 3 Multinational Medical Unit at Kandahar Airfield, Afghanistan, and as ID division chief and fellowship director in San Diego. He retired from active duty in 2021 and joined the faculty at Wake Forest. He is the chair of the ABIM Critical Care Medicine Examination Board, co-chair of the SCCM Congress Program Committee, and Chair-Elect of the Chest Infections and Disaster Response Network in CHEST, as well as deputy editor for outreach for the journal CHEST and contributing editor for Critical Care Explorations. He is an author of over 150 scientific manuscripts, 15 textbook chapters, and 100 conference abstracts and invited lectures. He lives in Winston-Salem with his wife, Robin, whom he met in the traditional manner (in the ICU, next to a...

In this episode, Dr. Qoot Alkhubaizi, Assistant Dean of Clinical Affairs at the University of Maryland School of Dentistry (UMSOD), joins the podcast to share her journey in dentistry, insights on global oral health, and how digital innovations and AI are shaping the future of dental education and patient care.

In this episode, Dr. Qoot Alkhubaizi, Assistant Dean of Clinical Affairs at the University of Maryland School of Dentistry (UMSOD), joins the podcast to share her journey in dentistry, insights on global oral health, and how digital innovations and AI are shaping the future of dental education and patient care.

How This Is Building Me, hosted by world-renowned oncologist D. Ross Camidge, MD, PhD, is a podcast focused on the highs and lows, ups and downs of all those involved with cancer, cancer medicine, and cancer science across the full spectrum of life's experiences. In this episode, Dr Camidge sat down with Ken Culver, MD, the director of Research and Clinical Affairs at ALK Positive Inc.  Drs Camidge and Culver discussed the highlights of Dr Culver's career, which has been shaped by clinical practice, research, industry leadership, and patient advocacy. They noted elements of ALK Positive that set it apart from other patient advocacy groups, including its being entirely created, funded, and led by patients with stage IV lung cancer and their caregivers. Culver explained how he collaborates with patients to expand treatment opportunities, meets with companies and universities worldwide, and helps stakeholders recognize both the unmet needs and financial incentives for developing therapies for ALK-positive lung cancer. Culver detailed his path to the oncology field, which began with an intention to practice as a community pediatrician in Iowa. This led him to pursue residency training in California, where he gained diverse clinical experience, particularly in HIV/AIDS at the height of the epidemic. His early research explored HIV transmission in children born to drug-using mothers, highlighting the immunosuppressive effect of drug abuse even in the absence of HIV. During his fellowship, he contributed to pioneering work in gene therapy. He also participated in research that laid the groundwork for tumor-directed therapies, which later influenced large-scale clinical trials. Eventually, Culver explained that transitioned to industry. At Novartis, he contributed to the development of important drugs and witnessed the transformative launch of imatinib (Gleevec), one of the first targeted cancer therapies. Alongside his professional work, Culver established the Foundation for Peace, a nonprofit providing medical and community support in the Dominican Republic, Haiti, and Kenya. This initiative, which began with a mission trip in 1989, has grown to involve hundreds of volunteers annually, offering both medical care and broader community services. In his current role with ALK Positive, Culver noted that he has leveraged patient-led advocacy to influence industry priorities, resulting in several new clinical trials for ALK-positive patients. His work emphasizes balancing discovery research with near-term clinical opportunities to directly benefit patients with cancer today. He also shared how he prioritizes tools to empower patients, such as clinical trial finders, and stressed the importance of having contingency plans before disease progression. Overall, this conversation highlights a career that reflects a consistent commitment to science, patient care, and global service, guided by both professional and humanitarian values.

Dean's Chat hosts, Drs. Jensen and Richey, welcome Dr. Laura Brinker to the podcast! Laura Brinker, DPM, was previously a Vice President of Clinical Affairs at Paragon 28, where she drove innovation in foot and ankle surgical solutions. She now has a consulting firm to address advancements of medical devices, regulatory compliance, and clinical trials. With a background in Mechanical Engineering from Purdue and a DPM from Temple University, she completed her residency at the University of Louisville/Jewish Hospital. Dr. Brinker has combined private practice experience, clinical research, and engineering expertise to advance podiatric surgery and medical device development. Enjoy this entrepreneurial discussion with a young leader in our profession!

Intelligent Bio Solutions (Nasdaq: INBS) is harnessing the power of its unique medical technology, the Intelligent Fingerprinting Drug Testing Solution, to develop transformative solutions that improve quality of life.We're joined by Dr. Daniel Brown, Head of Clinical Affairs, and Dr. Paul Wilson, Head of Special Projects, as they provide a brief history of Intelligent Fingerprinting Technology, explain how it works, and discuss the company's intellectual property portfolio.Learn more: https://ibs.inc/Watch the full YouTube interview here: https://youtu.be/ZmLPgGdybW8And follow us to stay updated: https://www.youtube.com/@GlobalOneMedia?sub_confirmation=1

Dr. Brittany Partain, Associate Director of Clinical Affairs and Physician Education at Exagen has a background in biomedical engineering and a passion for problem-solving, Brittany has carved out a unique role at the intersection of diagnostics, clinical education and biotech innovationIn this episode, we explore why autoimmune diseases like lupus and rheumatoid arthritis are so difficult to diagnose, and how Brittany is helping close that gap through physician education and the use of novel T-cell biomarkers. We also talk about building trust with clinicians, misconceptions around diagnostic tools, and the real challenges of advancing innovation in a field that's historically lagging behind specialities like oncology. Finally, Brittany reflects on her journey as a female leader in MedTech, the importance of collaboration, and why passion matters when navigating a fast-paced, highly regulated industryTimestamps:[00:00:45] Why Autoimmune Diseases Are So Difficult to Diagnose[00:01:55] From Biomedical Engineering to Clinical Affairs[00:04:34] Why Rheumatology Has Lagged Behind[00:07:07] How T-Cell Biomarkers Work and What They Solve[00:09:18] What Autoimmune Diseases Are and How They Present[00:11:05] Common Misconceptions Among Clinicians[00:13:00] How Hospitals and Private Clinics React to New Tools[00:15:07] Building Clinical Trust Through Science[00:18:05] What Most People Don't Know About Autoimmune Disease[00:21:58] Women in Biotech: Breaking Stereotypes and Leading ChangeGet in touch with Brittany - https://www.linkedin.com/in/brittany-d-partain Learn more about Exagen - https://exagen.com/ Get in touch with Karandeep Badwal - https://www.linkedin.com/in/karandeepbadwal/ Follow Karandeep on YouTube - https://www.youtube.com/@KarandeepBadwalSubscribe to the Podcast

Aislinn Walsh, lost her 32-year-old husband, Tom, to melanoma in April last year // Amy Nolan, Director of Clinical Affairs with The Irish Cancer Society.

Leadership development is more than titles and advancement—it's a continual process of growth, self-discovery, and adaptation. Part two of our Lifecycle of Leadership series with the Association of Departments of Family Medicine (ADFM) explores how leaders find their voice, navigate common pitfalls like micromanagement and impostor syndrome, and learn to delegate with purpose. Seasoned leaders, Peter Catinella, MD, and Jehni Robinson, MD, FAAFP, discuss the challenges of introverts and extroverts, the importance of mentorship, mastering the language of leadership, and balancing impact with well-being. Our guests offer real-world insights on leading with clarity and intention while embracing progress over perfection.Hosted by Omari A. Hodge, MD, FAAFP and Jay-Sheree Allen Akambase, MDCopyright © Society of Teachers of Family Medicine, 2025Resources:Emerging Leaders FellowshipLeadership through Scholarship FellowshipFamily Medicine Leadership Development OpportunitiesLeadership Opportunities - How to get involved at STFMADFM Leader Development Committee -  Resources from the Leader Development Committee for New & Interim ChairsADFM LEADS FellowshipPeter Catinella, MDDr Catinella has over 30 years of experience in several academic institutions, and currently serves as the as Department Chair at Texas Tech Health Sciences Center El Paso Department of Family Medicine-Transmountain. His prior leadership positions included serving as the Chief Medical Information Officer at the University of Arizona's Health Network and the Clinical Vice Chair in the Department of Family & Community Medicine at the University of Arizona-Tucson, Vice Chair for Clinical Affairs at the Department of Family & Preventive Medicine at the University of Utah and as Director of its Public Health Program, and residency program director at Indiana University. He recently chaired the Leader Development Committee of the Association of Departments of Family Medicine and was a member of its Board of Directors during that tenure.Dr Catinella received his medical degree from the University of Arizona College of Medicine and his Master of Public Health from the University of South Florida. He completed his residency in Family Medicine at Banner Good Samaritan Medical Center in Phoenix, and is certified by the American Board of Family Medicine.Jehni Robinson, MD, FAAFPDr Jehni Robinson is a Professor and Chair of the Department of Family Medicine and Associate Dean for Primary Care at the Keck School of Medicine at the University of Southern California in Los Angeles, CA. She is President of the Association of Departments of Family Medicine (ADFM). Dr Robinson led development of a new Family Medicine residency, graduating its first class in 2024 and co-founded USC Street Medicine Program in 2018, which brings care to unhoused people in Los Angeles. She received the Society of Teachers of Family Medicine (STFM) Advocate Award for this work .  Prior to coming to USC, she served as Chief Medical Officer for The Saban Free Clinic, also known as The Los Angeles Free Clinic, and taught in the Harbor UCLA Transforming Primary Care Faculty Development Fellowship. She received her undergraduate degree from Stanford and her medical degree from Morehouse School of Medicine. She comple

LTBS host Dr. Joel Berg sits down with incoming American Academy of Pediatric Dentistry President Dr. Tom Ison to talk about his leadership journey. Dr. Ison shares how he felt the pull to specialize in pediatrics after practicing as a general dentist, and how that choice impacted him as a rural practitioner. He also delves into his agenda for the 25-26 Academy year, including honoring the legacy of the leaders who came before him. Recorded in front of a live audience at AAPD 2025, the conversation is a testament to the importance of professional organizations and the role they play in sharing expert information. Guest Bio: Dr. Thomas G. Ison is in private practice in Newburgh, Ind. He received his dental degree and certificate in pediatric dentistry from the University of Kentucky College of Dentistry and Chandler Medical Center in Lexington, Ky., and completed a Fellowship in Pediatric Dentistry at Indiana University School of Dentistry. He previously held appointments as an assistant professor at the University of Kentucky College of Dentistry and Chief of Dentistry at Norton Children's Hospital, in Louisville. He is a Fellow of the American Academy of Pediatric Dentistry and American College of Dentists, as well as a Diplomate of the American Board of Pediatric Dentistry. He has completed the AAPD Leadership Institute at Kellogg and the Advanced Leadership at Wharton. He served as a consultant to the AAPD Council of Clinical Affairs, District III (now Southeastern) Trustee and is a Past President of the Southeastern Society of Pediatric Dentistry and Kentucky Academy of Pediatric Dentistry. Dr. Ison has been an examiner for the ABPD Oral Clinical Exam as well as committee member and part leader for the Renewal of Certification Examination. He resides in Evansville, Ind., with his wife, Connie, and daughter, Maggie.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Lindsay Dougherty, International Vice President and Division Director of the Motion Picture and Theatrical Trade Division of the International Brotherhood of Teamsters and Principal Officer of Teamsters Local 399, joined the America's Work Force Union Podcast. Dougherty discussed the impact of tax incentives on production locations, the industry's contraction due to streaming and efforts to standardize contracts across the country. Merrilee Logue, Executive Director of the National Labor Office (NLO) at Blue Cross Blue Shield Association (BCBSA), and Dr. Ruthie Fesahazion-Fortune, Project Director for Clinical Affairs at BCBSA, discuss the mental health crisis facing American workers. In this episode of the America's Work Force Union Podcast, they explore common mental health challenges, workplace impacts and BCBSA's strategies to address these issues.

This episode, recorded live at the Becker's 3rd Annual Spring Payer Issues Roundtable, features Dr. Damanjeet Chaubey, Vice President of Clinical Affairs at Clover Health. Dr. Chaubey shares how Clover is leveraging AI-powered technology, proactive care models, and home-based strategies to improve outcomes, reduce costs, and redefine Medicare Advantage.

Are Vaccines Good For Us? Marschall S. Runge, M.D., Ph.D., was born in Austin, Texas, and graduated from Vanderbilt University with a BA in General Biology and a PhD in Molecular Biology. He received his medical degree from the Johns Hopkins School of Medicine and trained in internal medicine at Johns Hopkins Hospital. He was a cardiology fellow and junior faculty member at Massachusetts General Hospital. Dr. Runge's next position was at Emory University, where he directed the Cardiology Fellowship Training Program. He then moved to the University of Texas Medical Branch in Galveston, where he was Chief of Cardiology and Director of the Sealy Center for Molecular Cardiology. He joined the University of North Carolina (UNC) from 2000 – 2014, where he served as Charles Addison and Elizabeth Ann Sanders Distinguished Professor of Medicine, Chair of the Department of Medicine, President of UNC Physicians and Vice Dean for Clinical Affairs. Dr. Runge visits with Mark Alyn.Become a supporter of this podcast: https://www.spreaker.com/podcast/late-night-health-radio--2804369/support.

Are Vaccines Good For Us? Marschall S. Runge, M.D., Ph.D., was born in Austin, Texas, and graduated from Vanderbilt University with a BA in General Biology and a PhD in Molecular Biology. He received his medical degree from the Johns Hopkins School of Medicine and trained in internal medicine at Johns Hopkins Hospital. He was a cardiology fellow and junior faculty member at Massachusetts General Hospital. Dr. Runge's next position was at Emory University, where he directed the Cardiology Fellowship Training Program. He then moved to the University of Texas Medical Branch in Galveston, where he was Chief of Cardiology and Director of the Sealy Center for Molecular Cardiology. He joined the University of North Carolina (UNC) from 2000 – 2014, where he served as Charles Addison and Elizabeth Ann Sanders Distinguished Professor of Medicine, Chair of the Department of Medicine, President of UNC Physicians and Vice Dean for Clinical Affairs. Dr. Runge visits with Mark Alyn.Become a supporter of this podcast: https://www.spreaker.com/podcast/late-night-health-radio--2804369/support.

On Friday March 28th, the Irish Cancer Society (ICS) will celebrate Daffodil Day. It's the charity's biggest fundraising event and aims to raise millions of euros to support cancer patients and progress cancer research. In this episode, Kathy Sheridan is joined by Daffodil Day Ambassador Tara Doonan, who was diagnosed with breast cancer in 2022 at 36 years-old. Tara lives in Cavan but travelled to the Mater Hospital in Dublin for her treatment. In today's episode she talks about the shock of her diagnosis, the road to recovery and the financial impact of cancer, from travel and parking expenses, to the loss of income. Amy Nolan, Director of Clinical Affairs at ICS also joins the conversation to explain how the charity supports patients financially and what needs to change in order to limit costs for those undergoing treatment. But first Irish Times podcast presenter Bernice Harrison is here to discuss some of the biggest stories of the week including a frightening encounter at a Dublin hotel for influencer Chloe Koyce, the harassment of a University of Limerick student at her campus accommodation and the latest in the rumoured feud between Gwyneth Paltrow and Meghan Markle. Hosted on Acast. See acast.com/privacy for more information.

Brían French, brother of the late Eoin French // Amy Nolan, Director of Clinical Affairs with The Irish Cancer Society

KEY MILESTONES AND WHAT'S NEXTSuccessful Phase 1 Trial: Lucid-MS has shown excellent safety with no serious side effects, paving the way for a groundbreaking treatment for MS.Next Major Step: The Phase 2 trial is set for early 2026, with 60 participants.FDA Submission on the Horizon: Plans to submit application to the FDA by late 2025, taking a huge step toward regulatory approval.Massive Market Opportunity: With 2.9 million people worldwide affected by Multiple Sclerosis and the market projected to surpass $30 billion by 2030, Lucid-MS could potentially capture a significant share of this rapidly expanding space.A NEW ERA IN MULTIPLE SCLEROSIS TREATMENTQuantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) Lucid-MS is setting the stage to revolutionize MS treatment. Unlike existing therapies that only target immune system responses, Lucid-MS focuses on protecting and repairing myelin, the critical layer around nerve fibers. This novel approach has the potential to slow or even reverse disease progression—offering new hope for millions of MS sufferers.Think of nerves like electrical wires in your body, and myelin as the protective coating around those wires. With Multiple Sclerosis, the immune system attacks this coating (called demyelination), causing damage that leads to muscle weakness, vision problems, and difficulty moving.Most MS treatments try to calm the immune system to slow down the attack. Lucid-MS is different. Instead of focusing on the immune system, it works directly on the myelin to stabilize and protect it from damage.HOW DOES IT WORK? A TOTALLY NEW APPROACH TO TREATING MSThink of nerves like electrical wires in your body, and myelin as the protective coating around those wires. With Multiple Sclerosis, the immune system attacks this coating (called demyelination), causing damage that leads to muscle weakness, vision problems, and difficulty moving.Most MS treatments try to calm the immune system to slow down the attack. Lucid-MS is different. Instead of focusing on the immune system, it works directly on the myelin to stabilize and protect it from damage.WHY IS THIS IMPORTANT?By keeping myelin intact, Lucid-MS may help slow down the progression of MS and prevent disability—something current MS drugs don't do very well.SCIENTIFIC BREAKTHROUGH BACKED BY INDUSTRY RECOGNITIONLucid-MS is backed by cutting-edge research from Dr. Lakshmi Khotra's lab at the University of Toronto, where the critical process of myelin breakdown in MS patients was discovered. The drug's ability to address this underlying issue is a potential game-changer in neurodegenerative treatments.It's already gaining enthusiastic support from leading medical experts and researchers, underscoring its transformative potential.A VISION FOR THE FUTUREDr. Andrzej Chruscinski, Vice President of Scientific and Clinical Affairs at Quantum BioPharma, expressed the company's excitement about Lucid-MS's future.“We are on the cusp of something monumental. Lucid-MS has the potential to transform MS treatment and open doors for treating other nerve-related diseases. As we move toward Phase 2 and beyond, we're excited to bring this innovative therapy to the patients who need it most.”With promising clinical results, a massive market opportunity, and rising industry recognition, Quantum BioPharma is leading the charge in next-generation treatments for Multiple Sclerosis 

Physician Enterprise Grand Rounds session discussing best practices for Type 2 Diabetes Mellitus Management.Our speakers for the session are Mandeep Bajaj, MBBS, Vice Chair for Clinical Affairs and a Professor in the Department of Medicine at Baylor College of Medicine, and Avin P. Pothuloori, MD, Assistant Professor of Medicine at Creighton University School of Medicine.PanelistDebra Rockman, RN, MBA, System Vice President of Ambulatory Quality, CommonSpirit Health

In this episode of Dentistry Uncensored, Howard sits down with two industry leaders, Jason Goodchild, DMD, Vice President of Clinical Affairs at Premier Dental, and Paul Mondock, President of North America & Global Sales Services at Septodont. Together, they dive into the science and innovation behind BufferPro, a cutting-edge buffering solution that enhances the effectiveness of local anesthesia.   They discuss the game-changing benefits of buffering anesthetics, why it matters for both clinicians and patients, and how BufferPro stands out from other buffering methods. Learn about the collaboration between Premier Dental and Septodont, how BufferPro is used chairside, and how to integrate it into your practice.   Join Dentaltown! https://www.dentaltown.com/ And follow Dentaltown on social media! YouTube: https://www.youtube.com/@DentaltownMagazine LinkedIn: https://www.linkedin.com/company/farran-media-llc/ Twitter/X: https://x.com/dentaltown TikTok: https://www.tiktok.com/@dentaltown4 Facebook: https://www.facebook.com/Dentaltown/ Instagram: https://www.instagram.com/dentaltown/

EEG is the single most useful ancillary test to support the clinical diagnosis of epilepsy, but if used incorrectly it can lead to misdiagnosis and long-term mental and physical health sequelae. Its application requires proper understanding of its limitations and variability of testing results. In this episode, Katie Grouse, MD, FAAN, speaks with Daniel Weber, DO, author of the article “EEG in Epilepsy,” in the Continuum® February 2025 Epilepsy issue. Dr. Grouse is a Continuum® Audio interviewer and a clinical assistant professor at the University of California San Francisco in San Francisco, California. Dr. Weber is the director of adult epilepsy and vice chair of clinical affairs at the St. Louis University in St. Louis, Missouri. Additional Resources Read the article: EEG in Epilepsy Subscribe to Continuum: shop.lww.com/Continuum Earn CME (available only to AAN members): continpub.com/AudioCME Continuum® Aloud (verbatim audio-book style recordings of articles available only to Continuum® subscribers): continpub.com/Aloud More about the American Academy of Neurology: aan.com Social Media facebook.com/continuumcme @ContinuumAAN Guest: @drdanielweber Full episode transcript available here Dr Jones: This is Dr Lyell Jones, Editor-in-Chief of Continuum, the premier topic-based neurology clinical review and CME journal from the American Academy of Neurology. Thank you for joining us on Continuum Audio, which features conversations with Continuum's guest editors and authors who are the leading experts in their fields. Subscribers to the Continuum journal can read the full article or listen to verbatim recordings of the article and have access to exclusive interviews not featured on the podcast. Please visit the link in the episode notes for more information on the article, subscribing to the journal, and how to get CME. Dr Grouse: This is Dr Katie Grouse. Today, I'm interviewing Dr Daniel Weber about his article on EEG and epilepsy, which appears in the February 2025 Continuum issue on epilepsy. Welcome to the podcast and please introduce yourself to our audience. Dr Weber: Hi, thanks for having me. My name is Dan Weber and I'm an epileptologist at Saint Louis University. I direct the adult epilepsy program here and also serve as the vice chair for Clinical Affairs. Been my pleasure to work on this article. Dr Grouse: I'm so happy to have you today. I read your article. I found it to be incredibly useful as someone who often orders EEG in the general neurology clinic. So, I wanted to start with asking, what is the most clinically relevant message or takeaway from your article that you'd really like neurologists to know?  Dr Weber: Yes, when I was asked to write this article, I looked back at the previous Continuum on epilepsy and just the general literature. And there's a lot of good articles and books out there on EEG and epilepsy and sort of giving you a primer on what you might see and how to interpret it. So, we wanted to try to go a slightly different direction. This article gives you some of that gives you the background of EEG and some of the basic things that you may see, but the real thrust of it is more about the limitations of EEG in the clinical picture of epilepsy and common things you might avoid. There are some things that we get hammered into our brains in training that aren't always true and there's plenty of examples in the literature to review, and this article sort of tries to encapsulate as many of those as possible in a digestible format. The main takeaway would be that EEG is an extremely helpful tool in the diagnosis of epilepsy, is the best tool we have to help supplement your clinical acumen. But it does not make the diagnosis of epilepsy. And there are certain circumstances when it may not be as helpful as you may have been led to believe in residency. Dr Grouse: Maybe not the most comforting of messages, but certainly an important one, very important to learn more about this. So, we appreciate that. Can you tell us your decision-making process when deciding whether to order a routine EEG, an extended EEG, prolonged ambulatory EEG, or inpatient video EEG? Dr Weber: Sure. So, it's a multi-part question because each one, I think, has a different clinical scenario. In the current state, our best data for estimating risk of recurrence after an initial seizure comes with routine EEG abnormalities. So, often I will order routine EEGs in those scenarios. So new patient presentation, new patients coming in with an initial seizure who want to know what's their risk of recurrence. So, risk stratification, I use a lot of routine EEG for, often sleep deprived if possible to increase the sensitivity. If you'd like, the extended EEG does offer higher sensitivity, or you can repeat the routine EEG if the first routine EEG is nonconclusive. For generally extended EEGs, I tend to order them in my practice if patients have come to see me with a suspected diagnosis of epilepsy but haven't yet had any electrographic confirmation. Maybe they've already had routine EEGs done in the past, so we'll try to obtain just a little more data. The longer-term EEGs I tend to use in different clinical scenarios, in patients usually who already have established diagnosis or people who have become refractory and we haven't yet confirmed their diagnosis. I tend to do inpatient EEGs in those situations. Ambulatory EEGs I do more when there are certain characteristics of the patient or the patient 's presentation that may not fit well on the inpatient side. Patients who are reliant on substances who can't use while they're inpatient and may have withdrawal effects complicating the stay. Or people who have a strong activation component to their epilepsy where activity really draws it out, certain activities that they do at home that they might not do during the inpatient stay. Those are the sorts of people I'll do ambulatory EEGs on. There are a couple other scenarios as well that come up less commonly, but everything has its own little niche. Dr Grouse: That's a really helpful review as we sort of think about which way we want to go as we're working up our patients in the inventory setting. Can you tell me a little more about the difference between sensitivity of, for instance, doing maybe two routine EEGS versus prolonged ambulatory EEG? Dr Weber: Generally speaking, the longer you're recording someone's brain waves, the higher the sensitivity is going to be. So routine EEG is twenty to forty minutes at most places. One of those gives you a certain sensitivity. More of them will give you more sensitivity. And there was a recent study highlighted in the article that compared routine EEGs to initial multi-day ambulatory EEG, and the ambulatory EEG obviously, as would be expected, has a higher sensitivity than either of the routines. So, there may be some cases with that initial evaluation where an ambulatory EEG may be held and we get into that in more detail in the article. But with the caveat, a lot of this article is about limitations, and the data that we have to talk about increased risk of recurrence was based off seeing epileptic form discharges on routine EEG. So you could hypothesize that if you only have one epileptic form discharge in three days on an ambulatory EEG, that may not carry the same recurrent significance as catching one on a twenty minute EEG. But we don't have that knowledge. Dr Grouse: Getting a little bit more into what you mentioned about the limitations, when is the scalp EEG less useful or limited in the evaluation of epilepsy? Dr Weber: So, one thing I see a lot in my residence at here and other places where I've worked is, I get them very excited about EEG and they may order it a bit too much. So, if patients have a known, established diagnosis of epilepsy, electrographically confirmed, and they come in with a breakthrough seizure and they're back to their baseline, there's really not a strong reason to get an EEG. We often seem to in the emergency department as part of our evaluation, but we already know what happened to the patient. The patient's not doing poorly right now, so the EEG is not going to give you any additional information. Just like really any test, you should think, what are the possible outcomes of this test and how would those outcomes alter the care of this patient? And if no outcome is going to affect the care of the patient or give you any additional diagnostic information, then probably don't need to be doing that test. Dr Grouse: This is probably a good segue into asking, what is an area of confusion or common pitfalls that you've seen in the clinical application of EEG and epilepsy? Dr Weber: So, a lot of times on the inpatient service, we'll get longer-term EEGs for patients who are having spells that are occurrent while they're in the ICU or other places or altered in some way, encephalopathic. And these patients will have their spell, and in my report, I'll say that there is not any electrographic correlate. So, there's no EEG finding that goes along with the movement that they're doing that's concerning for a seizure. And that doesn't always mean that it's not an epileptic seizure. An EEG is not a one-hundred-percent tool. Epilepsy and seizures are a clinical diagnosis. The EEG is a helpful tool to guide that diagnosis, but it is not foolproof, so you need to take the whole clinical picture into account. Particularly focal seizures without impaired awareness often can be electrographically silent on surface EEG. If you see something that looks clinically like a seizure but doesn't show up on the EEG, there are circumstances that they get to in the paper a little bit where that can still be an epileptic seizure. And you just have to be aware of the limitations of the tests that you're ordering and always fall back on the clinical skills that you've learned. Dr Grouse: Are there any tips or tricks you can suggest to improve the clinical utility of EEG for diagnosis of epilepsy? And also thinking about the example you just gave, but maybe other cases as well? Dr Weber: Again, definitely need to incorporate EEG as part of a larger picture. The video component of EEG is incredibly helpful. You can't interpret EEG in isolation. Regardless of what the EEG shows, you can't make a diagnosis of epilepsy, but you certainly can be very suspicious of one. So, in those cases where you have a high suspicion for an epileptic seizure and the EEG has not given you any confirmatory evidence, it's really helpful to rely on any clinical expertise that you have access to. So, people who have seen lots of seizures may be helpful in that situation. Getting good recordings, good data to prove yourself one way or the other is helpful and continuing to evaluate. So usually, as I said, focal seizures that don't show up well on the EEG. People who have focal seizures will often have larger seizures if left untreated. So, you can try to admit them to an epilepsy monitoring unit where we try to provoke seizures and try to provoke a larger seizure to help confirm that diagnosis. Dr Grouse: This kind of gets into what we've already reviewed to some degree, but what is the easiest mistake to make (and hopefully avoid) when using EEG to diagnose epilepsy or make other treatment decisions? Dr Weber: I think the easiest, most common mistake I see is overreliance on the test. There's a lot of subjectivity to the interpretation of this test. There are a lot of studies out there on interrater reliability for epilepsy and intrarater reliability for epilepsy. We continue to try to make the findings more objective and get more quantified. The articles talk about our six criteria for epileptiform discharges and have reference to where that came from and the sorts of specificity that each of those criteria lead to. Just because an EEG report has said something, that does not diagnose or negate a clinical diagnosis of epilepsy. It is common for folks with non-epileptic seizures to have a history of reported epileptic form discharges on their EEG. Again, because there is some subjectivity to the test, some abnormal-looking normal variants will pop up and get interpreted as epileptiform discharges. It's important to review the whole patient, as much of the data as you can, and make the best clinical judgment you can of the overall case. Dr Grouse: What is quantitative EEG and how can it be clinically useful? Dr Weber: Now that most EEG is obtained digitally through the use of computer software, we have been able to employ computers to do a lot of the work for us. There are many different ways of looking at the EEG data, but it's all frequency bands over time. The quantitative EEG goal is really to simplify and condense what you're seeing on your normal EEG page into a more digestible format. Lets you look at a larger amount of data faster, which becomes more and more important as we're doing more of these long-term recordings, particularly in the intensive care unit. Quantitative EEG can help you assess a lot of data at a snapshot and get a general sense of what's going on with the patient over the past several hours. It does require some extra training to become familiar with it, but it's training that can be done at all levels. Again, it can help you see more, faster. Obviously, like everything, it has its own limitations. Sometimes the sensitivity and specificity may be a little off from the raw data review, and you should always go back to the raw data anytime there are questions. But it can be helpful to make things faster. Dr Grouse: Do you think you could give me a hypothetical example of a case where this would be something really nice to have?  Dr Weber: The most common example is folks with repetitive seizures in the ICU. If you're just looking at the raw data, you will get a sense of how often the seizures are happening. But if you look at the quantitative data, it sort of compresses that all down to a much smaller snapshot. So you can see much more readily, yes, these are how many seizures were happening. And here's where we gave our intervention; and look, there are fewer seizures after that intervention. So, it can help you assess response to treatment, help you assess just overall volume of seizures in a much more condensed fashion, and you can get through it much faster with the appropriate training. Dr Grouse: Can you tell us about any new developments in EEG that are on the horizon we should be aware of?  Dr Weber: Yeah. So, I think my two favorites, which I highlight in the article, are longer-term recordings---so, there's some companies that are working on subcutaneous EEG. So, implanted EEG electrodes that can stay in your body for the short, long term on the order of year or years and constantly send some EEG data. Obviously, it's not a full montage in most of those cases, but some EEG data that can help you assess long-term trends in epilepsy and long-term response to therapies. I think that's going to be really cool. I think it's very exciting and I think it'll change how we do clinical trials in the future. I think we'll be able to rely less on seizure diaries from folks and more on objective seizure data for patients who have these implanted. But with that will come an ever-increasing amount of data to be reviewed, which leads into the other exciting future trend is AI in the use of interpretations. AI is becoming more and more advanced and there are very exciting articles out on how good AI is getting at interpreting our EEGs. I think soon, in the very near future, the AI platforms will be able to dramatically reduce the amount of time it takes the experts to review an EEG. They'll be able to do a lot of the screening for us and then we can go back, just like I was talking about the quantitative EEG, go back and review segments of the raw data rather than having to review every page of every file, which is quite time consuming. Dr Grouse: Wow, that's really exciting. It certainly does seem like AI is making breakthroughs in just about every area of how we touch the practice of medicine. Exciting to hear that EEG is no exception. Dr Weber: Yeah, I'm fully excited. I think it's going to revolutionize what we're doing and also just greatly expand people's ability to access that level of expertise that the AI will offer. Dr Grouse: I wanted to transition to talking a little bit more about you and your career in neurology. How did you become interested in this area of neurology to begin with? Dr Weber: Yeah, it's sort of a roundabout fashion. So, I started out planning to be a neurointerventionalist, and then I realized that I didn't want that sort of call. For a hot minute in my PGI 3 year. I was planning to be a neuro-ICU doctor. I think that's largely because medicine is all I had been exposed to at that point and the ICU seemed like a very comfortable place. Then as I transitioned into PGI 3 we started doing more electives and outpatient rotations in my residency. And then I was planning on being a movement disorder specialist or an epileptologist, couldn't make up my mind for the longest time. And then I started to like EEG more than I liked watching videos. So, tilted myself towards epilepsy and haven't looked back.  Dr Grouse: Well, I really appreciated you coming to talk with us today about your article. I can't recommend it enough to anyone out there, whoever treats patients with epilepsy or orders the EEGs, I just think it was just incredibly useful. And it was such a pleasure to have you. Dr Weber: Thank you very much for having me, Katie.  Dr Grouse: Again, today I've been interviewing Dr Daniel Weber about his article on EEG and epilepsy, which appears in the most recent issue of Continuum on Epilepsy. Be sure to check out Continuum Audio episodes from this and other issues. And thank you to our listeners for joining today. Dr Monteith: This is Dr Teshamae Monteith, Associate Editor of Continuum Audio. If you've enjoyed this episode, you'll love the journal, which is full of in-depth and clinically relevant information important for neurology practitioners. Use this link in the episode notes to learn more and subscribe. AAN members, you can get CME for listening to this interview by completing the evaluation at continpub.com/audioCME. Thank you for listening to Continuum Audio.  

Shienal Patel joins Liz in this episode to discuss how having strong investigator and clinical rep training strategies can impact the success of your product in the trial and into commercialization. In their discussion they explore why it's important to invest in training during the clinical trial, considerations for the level of training that needs to be offered, and the possible consequences for not providing great training. Shienal shares her own experiences and the key learnings she has had over her career. In 2025, we're embarking on a MedDevice Training Journey: From clinical trials to standard of care. Join us all year long as we explore training at each stage of the product life cycle. Related Resources: Shienal Patel is a highly accomplished clinical affairs leader with over two decades of experience in the medical device and pharmaceutical industries, specializing in ophthalmology. Currently serving as Vice President and Head of Clinical Affairs at Myra Vision, she oversees the development of the Calibreye TGT System for glaucoma treatment. Previously, at Genentech, as Senior Clinical Scientist and Operations Program Leader, Shienal was instrumental in advancing the Port Delivery System (PDS) for Susvimo and other pipeline programs in ophthalmology. Her leadership spanned from clinical trial design and execution to regulatory strategy, including critical collaborations with cross-functional teams and regulatory bodies. Shienal has also contributed significantly to early-stage device development at NESOS, focusing on vagus nerve stimulation therapies, and led global clinical operations for pivotal ophthalmology and respiratory programs at Genentech. Her efforts have earned her multiple Roche Product Development Breakthrough Awards and industry recognition for innovation and excellence. Subscribe to our newsletter to hear more about the journey from clinical trials to standard of care! ⁠Click here to subscribe! Connect with us on LinkedIn:   ⁠⁠⁠⁠⁠⁠⁠⁠⁠ Shienal Patel ⁠⁠⁠⁠⁠Cumby Consulting⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠Rachel Medeiros⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Liz Cumby⁠⁠⁠⁠⁠ About Cumby Consulting:    Cumby Consulting's team of professionals deliver innovative MedTech training services for physicians, sales representatives, teaching faculty, key opinion leaders and clinical development teams. Whether you need a complete training system developed to deliver revenue sooner or a discrete training program for a specific meeting, Cumby Consulting will deliver highly strategic, efficient programs with uncompromising standards of quality.

Doctor note generation at Freed focuses on customization and personalization, to build "something to make clinicians happy." Indeed, comments posted by physicians online about the product are highly positive, such as "I got two hours of my day back." In pursuit of personalization—without adding complexity to the interface—Freed starts a generic ambient clinical note based on ChatGPT, then adds a post--processing step to adapt the tone and style of generated text to the medical specialty as well as to the individual physician's preferences. Jack Jeng, MD, Head of Clinical Affairs at Freed, says they started by targeting primary care, but have seen the product used for a wide variety of specialties, notably mental health, physical therapy, and occupational therapy. Their market is small to medium-sized practices. Learn more about Freed: https://www.getfreed.ai/ AI Medical Scribe Companies: https://www.healthcareittoday.com/ambient-clinical-voice-companies/

Send us a textIn this episode of Going Under: Anesthesia Answered, Dr. Brian Schmutzler and Vahid Sadrzadeh are in studio joined by Bronson Taylor. Taylor is the Vice President of Clinical Affairs for CCI Anesthesia and serves as the  Chief Clinical Officer at JEBS Anesthesia Management.Taylor, Dr. Schmutzler and Sadrzadeh discuss the next wave of viruses to potentially hit the United States, the aftermath of Covid-19 and vaccines!About Bronson Taylor :  https://www.ccianesthesia.com/leadership/bronson-taylor-crna/Have a question for Dr. Brian Schmutzler? Submit them to any of the social media pages below or on his website at https://www.drbrianschmutzler.com/Facebook: https://www.facebook.com/drbrianschmutzlerInstagram: https://www.instagram.com/drbrianschmutzlerTikTok: https://www.tiktok.com/@drbrianschmutzler?lang=enProvider or Medical Student?? Subscribe to his Patreon Page to get exclusive content and access to Medical Blocks:https://www.patreon.com/user?u=89356957&utm_medium=clipboard_copy&utm_source=copyLink&utm_campaign=creatorshare_creator&utm_content=join_linkThanks to our show sponsor: Butterfly Networkhttps://store.butterflynetwork.com/us/en/?rsCode=BRIAN25Support the show

Listen to the full episode here: https://youtu.be/NHgsW0l4mf8?si=MXfk9odHeMwBEGRX  Have you ever wondered why America is the fattest country in the world, with 75% of the population overweight and 42% obese? In this Habits and Hustle bonus episode, Dr. Mark Hyman shares eye-opening insights into the root causes of this epidemic. We discuss how ultra-processed foods disrupt our biology, leading to cravings and overeating as our bodies search for missing nutrients. We also discuss the staggering healthcare costs of metabolic dysfunction and chronic diseases driven by the Standard American Diet. Mark Hyman, MD is a practicing family physician and an internationally recognized leader, speaker, educator, and advocate in the field of Functional Medicine. He is the founder and director of The UltraWellness Center, Founder and Senior Advisor for the Cleveland Clinic Center for Functional Medicine, a fifteen-time New York Times best-selling author, and Board President for Clinical Affairs for The Institute for Functional Medicine. He is the founder and chairman of the Food Fix Campaign, dedicated to transforming our food and agriculture system through policy. He is a co-founder and the Chief Medical Officer of Function Health. He is the host of one of the leading health podcasts, The Doctor's Farmacy with 150+ million downloads. Dr. Hyman is a regular medical contributor to several television shows and networks, including CBS This Morning, Today, Good Morning America, The View, Fox, and CNN. What We Discuss: Ultra-processed foods and weight gain America's obesity and chronic disease crisis Metabolic dysfunction prevalence in the U.S. Economic costs of preventable chronic diseases Fad diets vs. eating real, quality foods Reversing cognitive decline and Alzheimer's disease Rising rates of Alzheimer's and its root causes Toxins in the food supply and environment Differences in food regulations between the U.S. and Europe …and more! Thank you to our sponsors: AquaTru: Get 20% off any purifier at aquatru.com with code HUSTLE Therasage: Head over to therasage.com and use code Be Bold for 15% off  TruNiagen: Head over to truniagen.com and use code HUSTLE20 to get $20 off any purchase over $100. Magic Mind: Head over to www.magicmind.com/jen and use code Jen at checkout. BiOptimizers: Want to try Magnesium Breakthrough? Go to https://bioptimizers.com/jennifercohen and use promo code JC10 at checkout to save 10% off your purchase. Timeline Nutrition: Get 10% off your first order at timeline.com/cohen Air Doctor: Go to airdoctorpro.com and use promo code HUSTLE for up to $300 off and a 3-year warranty on air purifiers.    Find more from Jen:  Website: https://www.jennifercohen.com/ Instagram: @therealjencohen   Books: https://www.jennifercohen.com/books Speaking: https://www.jennifercohen.com/speaking-engagement Find more from Dr. Mark Hyman: Website: https://drhyman.com/  www.functionhealth.com use code HUSTLE100 to save Podcast: The Doctor's Pharmacy

In this episode of the 5-Minute Check In with Dr. Thomas McGinn, Infectious Disease expert Dr. Renuga Vivekanandan joins us for an update on the winter virus season.Topics Discussed:InfluenzaCOVID-19RSVPneumoniaDisease X*Guest: Renuga Vivekanandan, MD, Infectious Disease Expert, Division VP and CMO Physician Enterprise - Midwest, Professor, Associate Dean for Clinical Affairs, Creighton University School of Medicine*Disease X was identified as malaria after this recording. Learn more:https://www.cbsnews.com/news/congo-mystery-disease-identified-severe-malaria-deaths-women-children/

In this episode of Medtech Talk, host Geoff Pardo speaks with Michael Jaff, DO, chief medical officer and vice president of Clinical Affairs, Technology, and Innovation at Boston Scientific. Dr. Jaff has a long list of achievements and a robust background as a professor of Medicine at Harvard Medical School, president of Newton-Wellesley Hospital, medical director at the Massachusetts General Hospital, and more. Dr. Jaff shares his thoughts on good leadership, medical device innovation (and how they can help hospitals succeed), and how hospitals and manufacturers can navigate post-COVID-19 financial strains. He also discusses his journey from clinician to hospital CEO to the manufacturing industry, as well as Boston Scientific's outlook on the future.  Medtech Talk Links:  Cambridge Healthtech Institute   Medtech Talk  Gilde Healthcare  Boston Scientific: Boston Scientific 

Is 93.2% of America metabolically unhealthy? According to Dr. Mark Hyman, yes. In this Habits and Hustle episode, I am joined by functional medicine pioneer Dr. Mark Hyman, to discuss America's declining health due to our ultra-processed diet and lifestyle choices. We dive into why we need simple changes to food quality, his practical approach to supplements, and controversial topics like Ozempic. We also discuss an exclusive discount code for listeners to get early access to Dr. Hyman's comprehensive health testing. Mark Hyman, MD is a practicing family physician and an internationally recognized leader, speaker, educator, and advocate in the field of Functional Medicine. He is the founder and director of The UltraWellness Center, Founder and Senior Advisor for the Cleveland Clinic Center for Functional Medicine, a fifteen-time New York Times best-selling author, and Board President for Clinical Affairs for The Institute for Functional Medicine. He is the founder and chairman of the Food Fix Campaign, dedicated to transforming our food and agriculture system through policy. He is a co-founder and the Chief Medical Officer of Function Health. He is the host of one of the leading health podcasts, The Doctor's Farmacy with 150+ million downloads. Dr. Hyman is a regular medical contributor to several television shows and networks, including CBS This Morning, Today, Good Morning America, The View, Fox, and CNN. What We Discuss: (00:00) Longevity, Aging, and Wellness (10:16) Functional Medicine and Inflammation Reset (15:47) Protein, Strength, and Cardio for Aging (25:25) Personalized Nutrition and Health Monitoring (35:23) Comprehensive Personalized Health Testing and Insights (48:00) America's Obesity Crisis and Chronic Disease (01:02:02) Body-Mind Connection in Longevity …and more! Thank you to our sponsors: AquaTru: Get 20% off any purifier at aquatru.com with code HUSTLE Therasage: Head over to therasage.com and use code Be Bold for 15% off  TruNiagen: Head over to truniagen.com and use code HUSTLE20 to get $20 off any purchase over $100. Magic Mind: Head over to www.magicmind.com/jen and use code Jen at checkout. BiOptimizers: Want to try Magnesium Breakthrough? Go to https://bioptimizers.com/jennifercohen and use promo code JC10 at checkout to save 10% off your purchase. Timeline Nutrition: Get 10% off your first order at timeline.com/cohen Air Doctor: Go to airdoctorpro.com and use promo code HUSTLE for up to $300 off and a 3-year warranty on air purifiers.    Find more from Jen:  Website: https://www.jennifercohen.com/ Instagram: @therealjencohen   Books: https://www.jennifercohen.com/books Speaking: https://www.jennifercohen.com/speaking-engagement Find more from Dr. Mark Hyman: Website: https://drhyman.com/  www.functionhealth.com use code HUSTLE100 to save Podcast: The Doctor's Pharmacy

Dr. Lisa Rosenthal, Chief of the Division of Consultation Psychiatry and Associate Vice Chair for Clinical Affairs in the Department of Psychiatry and Behavioral Sciences at Northwestern University, joins the show to talk about a program that focuses on evidence-based mental health services. Lisa explores the many facets to this program that not only provides […]

So you want validated, at-home, self-collected swabs for STI testing… Here's what you need to know!  Sexually transmitted infection rates continue to climb across the US and while testing for these diseases is widely available, for the most part it requires the patient to go to a local clinic to collect and submit their sample for testing. But, is that really necessary, especially from a test accuracy perspective? Today's guests answer that exact question. And I'm sure that many, if not all of us would agree that the ability for patients to collect samples outside of a clinical setting has numerous benefits, including what the authors refer to as pseudo-anonymity, increased comfort and ultimately increased access to testing, which would be of particular value for patients that may avoid clinical settings due to various different socioeconomic barriers.  Watch this episode: https://youtu.be/40XCHpAFvqw Guests: Dr. Breland Hockman, who is a board certified clinical chemist and the Director of Clinical Affairs at LetsGetChecked.com Dr. Dina Greene, Clinical Professor at University of Washington, Department of Laboratory Medicine and Pathology and former Associate Lab Director at LetsGetChecked.com Links: Overcoming analytical and preanalytical challenges associated with extragenital home collected STI specimens Join ASM for up to 50% off the publication fees when you publish in JCM or any of the ASM journals. This episode of Editors in Conversation is brought to you by the Journal of Clinical Microbiology and hosted by JCM Editor in Chief, Alex McAdam and Dr. Elli Theel. JCM is available at https://jcm.asm.org and on https://twitter.com/JClinMicro. Visit journals.asm.org/journal/jcm to read articles and/or submit a manuscript. Follow JCM on Twitter/

The syphilis epidemic in the U.S. is a growing public health crisis, with rates increasing by 76% from 2018 to 2022. Syphilis is preventable and curable, but early detection is key—especially for pregnant women, where timely testing can prevent congenital syphilis. Don't miss this episode on the solutions to this growing epidemic.    About Our Speaker: Dr. Lily Li is the Senior Director of Medical, Scientific & Clinical Affairs at QuidelOrtho. With a medical degree from Peking University and a PhD in Immunology from the University of Alberta, Dr. Li has guided the development of multiple infectious disease diagnostic tests at QuidelOrtho.  

Topics covered: - Defining antimicrobial stewardship- New randomized clinical trial looking at how stewardship prompts improve antibiotic selection for pneumonia- Resources and how CommonSpirit Health is taking action and addressing this important topicGuest expert: Dr. Renuga Vivekanandan, Infectious Disease Expert, Division VP and CMO Physician Enterprise - Midwest, Professor, Associate Dean for Clinical Affairs, Creighton University School of Medicine

In this episode, Dr. Angelo Milazzo, Vice Chair of Practice and Clinical Affairs at Duke Health, shares his insights on the evolving landscape of pediatric healthcare. He discusses priorities in workforce challenges, access to care, and the importance of community health management, while also highlighting innovative tools like AI to improve patient and provider experiences.

In this episode, Dr. Angelo Milazzo, Vice Chair of Practice and Clinical Affairs at Duke Health, shares his insights on the evolving landscape of pediatric healthcare. He discusses priorities in workforce challenges, access to care, and the importance of community health management, while also highlighting innovative tools like AI to improve patient and provider experiences.

In this episode, Dr. Angelo Milazzo, Vice Chair of Practice and Clinical Affairs at Duke Health, shares his insights on the evolving landscape of pediatric healthcare. He discusses priorities in workforce challenges, access to care, and the importance of community health management, while also highlighting innovative tools like AI to improve patient and provider experiences.

Infectious Disease expert Dr. Renuga Vivekanandan joins us for a preview of what to expect this season. Topics covered:- Viruses- Influenza- COVID-19- RSV- West Nile- MPox - VaccinesGuest: Dr. Renuga Vivekanandan, infectious Disease expert and Division VP and CMO Physician Enterprise - Midwest, Professor, Associate Dean for Clinical Affairs, Creighton University School of Medicine.

Mark Hyman, MD is a practicing family physician and an internationally recognized leader, speaker, educator, and advocate in the field of Functional Medicine. He is the Senior Advisor for the Cleveland Clinic Center for Functional Medicine, a fifteen-time New York Times best-selling author, and Board President for Clinical Affairs for The Institute for Functional Medicine. He is the founder and chairman of the Food Fix Campaign, dedicated to transforming our food and agriculture system through policy. He joins the show to discuss the transition from wellness to illness, how we develop chronic conditions and the specific foundational things we should all be doing for our health. We also talk about practicing systems medicine, the interconnectedness of the body, and the future of healthcare. Go to functionhealth.com and use code BLONDEFILES100, which allows 100 listeners to skip Function's waitlist of over 250,000Subscribe to Patreon for exclusive weekly content: patreon.com/ArielleLorreThis episode may contain paid endorsements and advertisements for products and services. Individuals on the show may have a direct, or indirect financial interest in products, or services referred to in this episode.Visit article.com/BLONDE for $50 off your first purchase of $100 or more. Go to ritual.com/BLONDE for 25% off your first month. Visit drinklmnt.com/BLONDE for a free sample pack!Use MALK's store locator to find MALK Creamers at a store near you.Get who gets you, on eHarmony! Sign up today at eharmony.com.Go to helixsleep.com/Blonde for up to 30% off.Produced by Dear MediaSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

In this episode, I'm joined by Dr. Mohit Joshipura, the VP of Clinical Affairs at OpenLoop. Mohit shares his incredible journey from practicing internal medicine to becoming a key player in the digital health space. We dive deep into the world of clinical operations and what it takes to transition from a traditional medical career to leading in health tech. If you're looking to pivot your career and want to understand the nuts and bolts of clinical operations, this episode is a goldmine.Quotes:"You can't be experienced without getting experience. Sometimes, you just need someone to take that leap of faith in you." - Dr. Mohit Joshipura"As clinicians, we tend to underestimate ourselves when it comes to getting involved beyond the exam room." - Dr. Mohit Joshipura"The transition from being a clinician to a health tech operator is far easier than the reverse." - Dr. Mohit Joshipura"In health tech, every conversation and LinkedIn update is an opportunity to grow your brand." - Dr. Mohit Joshipura"It's like residency all over again baptism by fire, drinking from a fire hose, building a plane while flying it." - Dr. Mohit JoshipuraShow Notes:The challenges of transitioning from clinical practice to digital health.How to build a career in clinical operations.The importance of cross-functional communication in health tech.Why humility and adaptability are key in the startup world.How to balance clinical rigor with operational demands.Links: https://www.matchday.health/https://www.linkedin.com/in/mohit-joshipura-md-9083201/https://openloophealth.com/?utm_source=linkedin 

Dr. Kelly Olson: Putting The Focus on Fentanyl | The Hopeaholics PodcastIn this thought-provoking episode of The Hopeaholics Podcast, we are joined by Dr. Kelly Olson, a renowned neuroscientist and the Associate Director of Clinical Affairs at Millennium Health. Dr. Olson delves into her extensive work on addiction, sharing insights from the groundbreaking reports she has conducted with Millennium Health.With a rich background in molecular neuroscience, Dr. Olson has dedicated her career to understanding the complexities of addiction and its impact on the brain. In this episode, she discusses the latest findings from Millennium Health's studies, exploring the patterns of substance use and the emerging trends that are shaping the future of addiction treatment.Dr. Olson also sheds light on how these reports are helping healthcare professionals and policymakers develop more effective strategies to combat addiction. Her expertise in neuropharmacology and integrative medicine offers listeners a deeper understanding of the biological and psychological factors that contribute to addiction.Join us as Dr. Kelly Olson shares her invaluable knowledge and experience, offering a unique perspective on the challenges and opportunities in the fight against addiction. Whether you're a healthcare professional, someone affected by addiction, or simply interested in the science behind it, this episode provides crucial insights into the ongoing battle against substance abuse.Follow us on all our social media platforms down belowINSTAGRAM : https://www.instagram.com/thehopeaholics/?igshid=Mzc1MmZhNjY%3DSPOTIFY: https://open.spotify.com/show/4diCrlmIyqrkE2e22mFgU1?si=2df7f5920f944098FACEBOOK: https://www.facebook.com/thehopeaholicspodcast/TREATMENT : https://www.hopebythesea.com

Steve Thorne, Founder & CEO of PDS Health and Dr. Tom Schwieterman, Chief Medical Officer & VP of Clinical Affairs of Midmark Corporation discuss the integration of dental and medical services. Highlights include: Pacific Dental Services rebranded as PDS Health Dr. Schwieterman's perspective as an MD Understanding clinical support in med-dent New diagnostics How does medical-dental integration work? For more information on PDS Health visit https://pdshealth.com To learn more about Midmark Corporation visit https://www.midmark.com/ If you like our podcast, please give us a ⭐⭐⭐⭐⭐ review on iTunes https://apple.co/2Nejsfa and a Thumbs Up on YouTube.

In this episode, Matt Iorio at Neuros Medical and Duane Mancini discuss his background in the Medtech space, the collection of clinical data, the importance of clinical data for regulatory and commercial purposes, and so much more.

In this episode, Sasank Kalipatnapu (@ksasank), John Culhane and Leana Dogbe (@ldogbe4) sit down along with Dr. Dalman (@RLDalmanMD) as chair of the SVS Nominating Committee for this year, along with the two vice presidential candidates Dr. Harris and Dr Shaw to learn more about them as part of the ongoing election process.    Show links: SVS 2024 Meet the VP Candidates—Home Page—provides a comprehensive overview of all the candidates. Their professional biographies and answers to questions about their plans for the future are available in both text and video formats.   Show Guests: Dr. Linda Harris, Professor of Surgery at Jacobs School of Medicine and Biomedical Sciences, University of Buffalo, NY Dr. Palma Shaw, Professor of Surgery at State University of New York, Syracuse, NY Dr. Ronald L. Dalman, Elsa R. and Walter C. Chidester Professor and Division Chief Emeritus of Vascular Surgery at Stanford University, CA, Associate Dean for Market Development and Outreach for Stanford Medicine and Vice Chair for Clinical Affairs in the Department of Surgery    Follow us @audiblebleeding Learn more about us at https://www.audiblebleeding.com/about-1/ and provide us with your feedback with our listener survey.

Don't forget to check out the video episode on YouTube!  In this episode, I interviewed Dr. Mike Barniv who has impressive street cred in the AI, carrier and clinical arenas. He's currently the VP of Clinical Affairs at Pearl. Dr. Barniv shared AI's role in treatment case acceptance. Hint - it helps tremendously! We had a frank talk about how the carriers are using AI in adjudication.  A few talking points:  How does AI help dentists to efficiently examine historical images to chart disease progression Using AI to meet carrier documentation criteria Is AI just denying everything?  This is one for the insurance nerds (my people

On today's podcast, I have the honor of speaking with former president of AAPA and current CMO and VP of Clinical Affairs of AAPA, Jennifer Orozco. We discuss advocacy, making an impact, and how to get a seat at the table.  Jenn stresses the importance of removing barriers to PA practice because healthcare can't afford to keep these barriers. PAs are experts in their fields and need to share their knowledge, experience and expertise with policy makers and those in leadership making decisions. Every PA has a powerful voice, and Jenn outlines ways in which we can start taking action today.  We don't need to ask for permission to share our ideas or opinions. We need to think bigger than just our own clinic and our own hospital system. We need to be bold in sharing our expertise so that we can make positive changes in healthcare.  Press play to hear inspiration and a call to action so that we can keep moving the PA profession and the American healthcare system forward in a positive direction.  SPONSORS ADVANCED SCOPE www.advancedscopetalent.com ADVANCED PRACTICE PLANNING https://www.advancedpracticeplanning.com/ COACHING ⁠1-ON-1 NEGOTIATION CONSULT https://calendly.com/the-pa-is-in/negotiate⁠  ⁠FREE 30-MINUTE COACHING CONSULT⁠ ⁠https://calendly.com/the-pa-is-in/gen-call⁠   LINKS CONNECT WITH JENNIFER: AAPA Website: https://www.aapa.org/ Jennifer's email: jorozco@aapa.org EPISODE BLOG POST https://www.tracybingaman.com/blog ⁠TRACY ON INSTAGRAM https://www.instagram.com/mrstracybingaman/⁠ ⁠TRACY ON LINKEDIN https://www.linkedin.com/in/tracybingaman/⁠ --- Support this podcast: https://podcasters.spotify.com/pod/show/thepaisin/support